Boule Diagnostics AB (publ)

OM:BOUL Stock Report

Market Cap: SEK 344.8m

Boule Diagnostics Future Growth

Future criteria checks 4/6

Boule Diagnostics is forecast to grow earnings and revenue by 103.4% and 6.2% per annum respectively. EPS is expected to grow by 103.3% per annum. Return on equity is forecast to be 15.6% in 3 years.

Key information

103.4%

Earnings growth rate

103.3%

EPS growth rate

Medical Equipment earnings growth36.7%
Revenue growth rate6.2%
Future return on equity15.6%
Analyst coverage

Low

Last updated02 Dec 2024

Recent future growth updates

Boule Diagnostics AB (publ) Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Jul 25
Boule Diagnostics AB (publ) Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Recent updates

Improved Revenues Required Before Boule Diagnostics AB (publ) (STO:BOUL) Stock's 26% Jump Looks Justified

Dec 03
Improved Revenues Required Before Boule Diagnostics AB (publ) (STO:BOUL) Stock's 26% Jump Looks Justified

Does Boule Diagnostics (STO:BOUL) Have A Healthy Balance Sheet?

Oct 10
Does Boule Diagnostics (STO:BOUL) Have A Healthy Balance Sheet?

Boule Diagnostics AB (publ) Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Jul 25
Boule Diagnostics AB (publ) Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Capital Allocation Trends At Boule Diagnostics (STO:BOUL) Aren't Ideal

Jul 24
Capital Allocation Trends At Boule Diagnostics (STO:BOUL) Aren't Ideal

Sentiment Still Eluding Boule Diagnostics AB (publ) (STO:BOUL)

Jun 06
Sentiment Still Eluding Boule Diagnostics AB (publ) (STO:BOUL)

Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

May 10
Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate

Mar 20
Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate

Here's What Analysts Are Forecasting For Boule Diagnostics AB (publ) (STO:BOUL) After Its Yearly Results

Feb 09
Here's What Analysts Are Forecasting For Boule Diagnostics AB (publ) (STO:BOUL) After Its Yearly Results

Boule Diagnostics AB (publ) (STO:BOUL) Screens Well But There Might Be A Catch

Dec 30
Boule Diagnostics AB (publ) (STO:BOUL) Screens Well But There Might Be A Catch

Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital

Jul 25
Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 49% Below Their Intrinsic Value Estimate

May 26
Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 49% Below Their Intrinsic Value Estimate

Boule Diagnostics' (STO:BOUL) Solid Profits Have Weak Fundamentals

Jul 26
Boule Diagnostics' (STO:BOUL) Solid Profits Have Weak Fundamentals

Returns On Capital Signal Tricky Times Ahead For Boule Diagnostics (STO:BOUL)

Jul 19
Returns On Capital Signal Tricky Times Ahead For Boule Diagnostics (STO:BOUL)

We Think Boule Diagnostics (STO:BOUL) Can Stay On Top Of Its Debt

Mar 06
We Think Boule Diagnostics (STO:BOUL) Can Stay On Top Of Its Debt

Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital

Feb 03
Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital

The Returns At Boule Diagnostics (STO:BOUL) Aren't Growing

Apr 29
The Returns At Boule Diagnostics (STO:BOUL) Aren't Growing

Should You Investigate Boule Diagnostics AB (publ) (STO:BOUL) At kr67.70?

Apr 09
Should You Investigate Boule Diagnostics AB (publ) (STO:BOUL) At kr67.70?

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 27% Below Their Intrinsic Value Estimate

Mar 25
Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 27% Below Their Intrinsic Value Estimate

Consider This Before Buying Boule Diagnostics AB (publ) (STO:BOUL) For The 1.0% Dividend

Mar 07
Consider This Before Buying Boule Diagnostics AB (publ) (STO:BOUL) For The 1.0% Dividend

Is Boule Diagnostics' (STO:BOUL) 210% Share Price Increase Well Justified?

Feb 17
Is Boule Diagnostics' (STO:BOUL) 210% Share Price Increase Well Justified?

These 4 Measures Indicate That Boule Diagnostics (STO:BOUL) Is Using Debt Extensively

Jan 30
These 4 Measures Indicate That Boule Diagnostics (STO:BOUL) Is Using Debt Extensively

Is Boule Diagnostics AB (publ)'s (STO:BOUL) Shareholder Ownership Skewed Towards Insiders?

Jan 14
Is Boule Diagnostics AB (publ)'s (STO:BOUL) Shareholder Ownership Skewed Towards Insiders?

How Many Boule Diagnostics AB (publ) (STO:BOUL) Shares Did Insiders Buy, In The Last Year?

Dec 28
How Many Boule Diagnostics AB (publ) (STO:BOUL) Shares Did Insiders Buy, In The Last Year?

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate

Dec 10
Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate

What Do The Returns On Capital At Boule Diagnostics (STO:BOUL) Tell Us?

Nov 22
What Do The Returns On Capital At Boule Diagnostics (STO:BOUL) Tell Us?

Earnings and Revenue Growth Forecasts

OM:BOUL - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20266425124622
12/31/20255914422592
12/31/2024559-21215552
9/30/2024563-213-2461N/A
6/30/202457321-783N/A
3/31/202457627-1573N/A
12/31/202357125-3151N/A
9/30/202357219-4336N/A
6/30/202355817-81-8N/A
3/31/202355916-91-19N/A
12/31/202254813-86-11N/A
9/30/202253927-87-13N/A
6/30/202252532-5614N/A
3/31/202249528-3229N/A
12/31/202146323-1343N/A
9/30/2021416-27357N/A
6/30/2021403-131464N/A
3/31/2021383-552573N/A
12/31/2020400-482975N/A
9/30/2020437-82670N/A
6/30/2020470-82976N/A
3/31/2020499352673N/A
12/31/201949938654N/A
9/30/201947632-1441N/A
6/30/201945621-3716N/A
3/31/201944436-5911N/A
12/31/201842441-4223N/A
9/30/201842548-1340N/A
6/30/201842460N/A51N/A
3/31/201842143N/A46N/A
12/31/201742837N/A58N/A
9/30/201742231N/A45N/A
6/30/201742128N/A38N/A
3/31/201741938N/A32N/A
12/31/201639736N/A20N/A
9/30/201638336N/A20N/A
6/30/201636422N/A28N/A
3/31/201634115N/A29N/A
12/31/201533115N/A22N/A
9/30/201533329N/A22N/A
6/30/201531833N/A8N/A
3/31/201530933N/A21N/A
12/31/201430730N/A31N/A
9/30/201428914N/A16N/A
6/30/2014285-68N/A35N/A
3/31/2014287-64N/A23N/A
12/31/2013277-70N/A16N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BOUL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).

Earnings vs Market: BOUL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BOUL is expected to become profitable in the next 3 years.

Revenue vs Market: BOUL's revenue (6.2% per year) is forecast to grow faster than the Swedish market (1.3% per year).

High Growth Revenue: BOUL's revenue (6.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BOUL's Return on Equity is forecast to be low in 3 years time (15.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 07:11
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Boule Diagnostics AB (publ) is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jakob LembkeABG Sundal Collier Sponsored
null nullABG Sundal Collier Sponsored
Christian LeePareto Securities